ZimVie Valuation
Is ZIMV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ZIMV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ZIMV * (MX$230) is trading below our estimate of fair value (MX$1177)
Significantly Below Fair Value: ZIMV * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ZIMV *?
Key metric: As ZIMV * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ZIMV *'s PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | US$894.02m |
| Market Cap | US$186.24m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 8.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ZIMV *'s PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.5x | ||
MEDICA B Médica Sur. de | 0.7x | 5.5% | Mex$3.1b |
688607 CareRay Digital Medical Technology | 4.6x | 25.1% | CN¥1.3b |
688067 AVE Science&TechnologyLTD | 6x | n/a | CN¥1.2b |
SOFW SofWave Medical | 2.7x | n/a | ₪558.1m |
ZIMV * ZimVie | 0.2x | -1.6% | Mex$186.2m |
Price-To-Sales vs Peers: ZIMV * is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (5.4x).
Price to Sales Ratio vs Industry
How does ZIMV *'s PS Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Sales vs Industry: ZIMV * is good value based on its Price-To-Sales Ratio (0.2x) compared to the Global Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is ZIMV *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ZIMV *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
-0.6%
1Y
-31.0%
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a
CONMED
US$2.2b
A medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide.
CNMD *
US$1,454.00
7D
0%
1Y
-22.8%